[Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia]

To investigate the efficacy and safety of decitabine combined with half-course pre-excitation for the treatment of elderly patients with acute myeloid leukemia (AML).44 cases of newly diagnosed elderly AML admitted in our hospital from January 2016 to December 2017 were selected for the retrospective analysis. The patients were randomly divided into 2 groups: pre-excitation therapy group as control and combined therapy group. The 22 patients in pre-excitation therapy group reccived the routine complete course pre-excitation treatment, 22 patients in combined therapy group received the desitabine combined the half course pre-excitation treatment. The therapentic efficacy and adverse reactions during treatment were compared between 2 groups. All patients were followed-up and the survival rate at 6,12 and 24 months was compared between 2 groups.The remission rate(RR) in the combined therapy group was 72.73%, and that in the control group was 50.00%, with significant statistically difference (P0.05). The median survival time in combined therapy group (17.82±4.19 months) and control group (12.43±3.71 months) was statistically significant (P0.05). The rate of adverse reactions of digestive tract in combined therapy group was 40.91%, which was higher than that in control group (18.18%), and the difference of two groups was statistically significant (P0.05). The incidence of adverse reactions in blood system and bone marrow suppression in combined therapy group was 9.09% and 68.18%, which were lower than those in control group (27.27% and 95.45%), with statistically significant differences (P0.05). There was no statistically significant difference in the incidence of liver dysfunction, cardiac insufficiency and hair loss between the two groups (P0.05). The incidence of pulmonary infection, intestinal infection and other complications in combined therapy group was 13.64%, which was lower than that in control group 31.82%, and the difference of two groups was statistically significant (P0.05). No serious complications such as arteriovenous thrombosis occurred in either group, and no patients died during chemotherapy.Combination of disitamine and half-course prestimulation treatmentis is a safe and effective and elderly patients with AML shown a good tolerance.地西他滨联合半程预激方案治疗老年急性髓系白血病患者的疗效与安全性观察.观察地西他滨联合半程预激方案治疗老年急性髓系白血病（AML）患者的疗效与安全性.选择本院2016年1月-2017年12月44例初诊的老年AML患者进行回顾性分析。根据治疗方案将患者分为2组：预激治疗组作为对照（22例）和联合治疗组（22例），前者采用常规全程预激治疗，后者采用地西他滨联合半程预激方案治疗。比较疗效和治疗期间副反应。所有患者均进行随访，比较2组6个月、12个月、24个月的生存率.联合治疗组RR为72.73%，对照组RR为50.00%，差异有统计学意义（P＜0.05）。联合治疗组中位生存时间为17.82±4.19个月，明显优于对照组中位生存时间（12.43±3.71个月）（P＜0.05）。联合治疗组消化道不良反应率为40.91%，明显高于对照组（18.18%）（P＜0.05）。联合治疗组血液系统不良反应率、骨髓抑制率分别为9.09%、68.18%，均明显低于对照组（27.27%和95.45%）（P＜0.05）。2组肝功能异常、心功能不全及脱发发生率差异无统计学意义(P＞0.05)。联合治疗组肺部感染、肠道感染等并发症发生率为13.64%，明显低于对照组（31.82%）（P＜0.05）。2组均无动静脉血栓等严重并发症发生，化疗期间无患者死亡.地西他滨联合半程预激方案治疗老年AML患者耐受性好，是适合老年AML患者安全有效的方法.